Related Experiment Video
Updated: Aug 4, 2025
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
PECAM1 plays a role in the pathogenesis and treatment of bone metastases
Zhuo-Tao Liang1,2, Jia-Ke Li3, Jiong Li1,2
1Department of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract:
Bone is the third most common metastatic site for all primary tumors, the common primary focus of bone metastases include breast cancer, prostate cancer, and so on. And the median survival time of patients with bone metastases is only 2-3 years. Therefore, it is urgent to develop new targets to diagnose and treat bone metastases. Based on two data sets GSE146661 and GSE77930 associated with bone metastases, it was found that 209 genes differentially expressed in bone metastases group and control group. PECAM1 was selected as hub-gene for the follow-up research after constructing protein-protein interaction (PPI) network and enrichment analysis. Moreover, q-PCR analysis verified that the expression of PECAM1 decreased in bone metastatic tumor tissues. PECAM1 was believed to be possibly related to the function of osteoclasts, we knocked down the expression of PECAM1 with shRNA in lymphocytes extracted from bone marrow nailed blood. The results indicated that sh-PECAM1 treatment could promote osteoclast differentiation, and the sh-PECAM1-treated osteoclast culture medium could significantly promote the proliferation and migration of tumor cells. These results suggested that PECAM1 may be a potential biomarker for the diagnosis and treatment of bone metastases of tumor.
Insights
Platelet endothelial cell adhesion molecule 1 (PECAM1) may be a key factor in bone metastasis. Lower PECAM1 levels promote tumor cell growth and migration, suggesting its potential as a diagnostic and therapeutic target for bone metastases.
Area of Science:
- Oncology
- Molecular Biology
- Biomarkers
Background:
- Bone metastases are a common and severe complication of many cancers, significantly reducing patient survival.
- Current diagnostic and therapeutic strategies for bone metastases are limited, highlighting the urgent need for novel targets.
- Identifying specific genes involved in bone metastasis is crucial for developing effective treatments.
Purpose of the Study:
- To identify potential molecular targets for diagnosing and treating bone metastases.
- To investigate the role of Platelet Endothelial Cell Adhesion Molecule 1 (PECAM1) in the context of bone metastasis.
Main Methods:
- Differential gene expression analysis using datasets GSE146661 and GSE77930.
- Construction of a protein-protein interaction (PPI) network and enrichment analysis to identify hub genes.
- Quantitative PCR (q-PCR) to validate PECAM1 expression levels.
- In vitro experiments involving PECAM1 knockdown using shRNA to assess its effect on osteoclast differentiation and tumor cell behavior.
Main Results:
- 209 differentially expressed genes were identified between bone metastatic and control groups.
- PECAM1 was identified as a hub gene and its expression was found to be decreased in bone metastatic tissues.
- Knockdown of PECAM1 promoted osteoclast differentiation.
- Culture medium from sh-PECAM1-treated osteoclasts enhanced tumor cell proliferation and migration.
Conclusions:
- PECAM1 expression is reduced in bone metastases and plays a role in regulating osteoclast function.
- Reduced PECAM1 promotes osteoclast differentiation, which in turn supports tumor cell proliferation and migration.
- PECAM1 represents a potential biomarker for the diagnosis and a therapeutic target for bone metastases.
More Related Videos
06:32Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
